Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 10:45 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 577–600 of 2,511 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Sequence Clear all

Conditions: Healthy Participants
Interventions: Immunoglobulin G; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 82 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 3
States / cities: Daytona Beach, Florida • Dallas, Texas • Madison, Wisconsin

Conditions: Infection, Human Immunodeficiency Virus
Interventions: BMS-663068, Oral Contraceptive, Loestrin 1.5/30; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 2
States / cities: Miami, Florida • San Antonio, Texas

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Glycopyrrolate (85 μg), Glycopyrrolate (42.5 μg), Glycopyrrolate (14 μg), Placebo; Drug
Lead sponsor: Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 7
States / cities: Clearwater, Florida • Tampa, Florida • Saint Charles, Missouri + 4 more

Conditions: Healthy
Interventions: Midazolam, PD-0332991; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: South Miami, Florida

Conditions: Initial Caries, Arrested Dental Caries, Cavitated Caries, Dental Caries, Dental Caries in Children
Interventions: Curodont Repair Fluoride Plus, Silver Diamine Fluoride, Glass Ionomer Sealant, Fluoride varnish, Fluoride toothpaste; Drug · Device
Lead sponsor: CareQuest Institute for Oral Health; Other
Eligibility: 4 Years and older
Enrollment: 744 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2024
U.S. locations: 4
States / cities: Dothan, Alabama • Westborough, Massachusetts • Bend, Oregon + 1 more

Conditions: Infection, Human Immunodeficiency Virus
Interventions: DTG/ABC/3TC FDC DISPERSIBLE TABLET, EPZICOM (ABC/3TC), TIVICAY (DTG); Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Urinary Incontinence
Interventions: PureWick System, UltraFlex Self-Adhering Male External Catheter; Device
Lead sponsor: C. R. Bard; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 15
States / cities: Guntersville, Alabama • Tucson, Arizona • Los Angeles, California + 11 more

Conditions: Prostate Cancer Aggressiveness
Interventions: Subtraction Normalized Expression of Phagocytes Blood Test; Diagnostic Test
Lead sponsor: Immunis.AI; Industry
Eligibility: 40 Years to 80 Years · Male only
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2029
U.S. locations: 1
States / cities: Royal Oak, Michigan

Conditions: Acute Respiratory Failure
Interventions: Rapid sequence intubation: sedative first, Rapid sequence intubation: paralytic first; Other
Lead sponsor: Hennepin Healthcare Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 335 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Age-Related Macular Degeneration
Interventions: KH658; Drug
Lead sponsor: Chengdu Origen Biotechnology Co., Ltd.; Industry
Eligibility: 50 Years to 85 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 3
States / cities: Phoenix, Arizona • Lemont, Illinois • Memphis, Tennessee

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Treatment A (BGF MDI HFO with oral activated charcoal), Treatment B (BGF MDI HFA with oral activated charcoal); Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 108 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Brooklyn, Maryland

Conditions: Seizures
Interventions: Oxcarbazepine; Drug
Lead sponsor: Roxane Laboratories; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Osteoarthritis, Knee, Osteoarthritis, Hip, Osteo Arthritis Shoulders, Synovitis of Knee, Synovitis/Tenosynovitis - Hip, Synovitis, Pain, Chronic
Interventions: Shoulder/Hip/Knee Embolization with Embozene Microspheres; Device
Lead sponsor: Palo Alto Veterans Institute for Research; Other
Eligibility: 25 Years to 80 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Healthy Volunteers
Interventions: Teduglutide, Syringe Injection, Pen injector; Drug · Device
Lead sponsor: Shire; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Healthy, Nervous System Disease
Interventions: Not listed
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: Not listed
Enrollment: 450 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1997 – 2003
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Healthy Volunteers
Interventions: Interference through learning of a competing motor skill., No interference; Behavioral
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years and older
Enrollment: 404 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Schizophrenia and Related Disorders
Interventions: Repetitive Transcranial Magnetic Stimulation (rTMS); Device
Lead sponsor: Columbia University; Other
Eligibility: 22 Years to 55 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: New York, New York

Conditions: Acute Myeloid Leukemia
Interventions: Phase I- Cytarabine & Eltrombopag, Phase II- Sequence A, Phase II- Sequence B; Drug
Lead sponsor: PrECOG, LLC.; Other
Eligibility: 18 Years to 70 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 5
States / cities: Worcester, Massachusetts • Rochester, Minnesota • Cleveland, Ohio + 2 more

Conditions: Lung Cancer
Interventions: comparative genomic hybridization, gene expression microarray analysis, proteomic profiling analysis, biologic sample preservation procedure, nasal brushing, Blood draw, Urine collection, sputum sample, fluorescence bronchoscopy with airway biopsy, fine needle aspiration of the lung, thoracentesis; Genetic · Other · Procedure
Lead sponsor: Vanderbilt-Ingram Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 4,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2027
U.S. locations: 2
States / cities: Nashville, Tennessee

Conditions: Obesity, Overweight
Interventions: UBT251, Cocktail (Warfarin/Caffeine/Midazolam); Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Cypress, California

Conditions: Caloric Intake
Interventions: Variety, Non-Variety; Behavioral
Lead sponsor: The University of Tennessee, Knoxville; Other
Eligibility: 3 Years to 6 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: Knoxville, Tennessee

Conditions: Healthy Participants
Interventions: Treatment A: Emraclidine 30mg IR tablets (reference), Treatment B: Emraclidine 30mg IR test tablets 1, Treatment C: Emraclidine 30mg IR test tablets 2, Treatment D: Emraclidine 30mg IR test tablets 3; Drug
Lead sponsor: Cerevel Therapeutics, LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Dilated Cardiomyopathy (DCM)
Interventions: RP-A701 is a recombinant viral vector composed of an AAV serotype rh.74 (AAVrh.74) capsid encapsulating the transgene, BCL2-associated Athanogene 3 (BAG3); Genetic
Lead sponsor: Rocket Pharmaceuticals Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 3
States / cities: San Diego, California • Rochester, Minnesota • Charleston, South Carolina

Conditions: Heathy Participants
Interventions: Treatment A (BDA MDI HFO), Treatment B (BDA MDI HFA); Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Glendale, California

Search by objective public record fields.

A Study to Assess the Tolerability and Safety of Subcutaneously (SC) Administered Immunoglobulin G (IgG) With Varying Injection Conditions

A Drug-drug Interaction Study Between BMS-663068 and Oral Contraceptives in Healthy Female Volunteers (DDI)

A Phase IIb Study of Glycopyrrolate Inhalation Solution Over 1 Week in Subjects With COPD

A Drug-Drug Interaction Study To Investigate The Potential For Multiple Doses Of Palbociclib (PD-0332991) To Alter The Pharmacokinetics Of Oral Midazolam In Adult Healthy Women of Non-Childbearing Potential.

Early Caries Lesion Management Observational Study

Relative Bioavailability Study of a Fixed-dose Combination Dolutegravir/Abacavir/Lamivudine Dispersible Tablet

An Evaluation of the PureWick™ Male External Catheter Versus an Established Comparator Overnight in the Home Setting for Incontinence in Adult Males

Active Surveillance SNEP Assay Registry Trial for Prostate Cancer

Drug Order for Rapid Sequence Intubation

A Phase I, Open-label, Multicenter, Dose-Escalating Study to Evaluate the Safety and Tolerability of KH658 Gene Therapy in Participants With Neovascular Age-related Macular Degeneration

Study to Assess the Lung Exposure Bioequivalence of Budesonide, Glycopyrronium, and Formoterol Delivered by BGF MDI With Next-Generation Propellant Compared With BGF MDI With HFA Propellant

Crossover Bioequivalence Study of Oxcarbazepine 600 mg Suspension Under Fasted Conditions

Perfusion MRI-targeted Joint Embolization for Chronic Musculoskeletal Pain of the Shoulder, Hip and Knee

A Study to Evaluate the Bioavailability of Teduglutide Administered Subcutaneously by Syringe Injection Versus Pen Injector in Healthy Adult Participants

Functional and Metabolic Imaging Using Magnetic Resonance Imaging and Spectroscopy

Reshaping the Motor Engram - An Online Crowdsourcing Study.

An Extension Protocol for Patients Who Previously Completed the TMS Pilot Study

Trial of Eltrombopag During Consolidation Therapy in Adults With AML in Complete Remission

Molecular Predictors of Cancer in Patients at High Risk of Lung Cancer

A Research Study on How UBT251 Affects Levels of Midazolam, Caffeine and Warfarin in the Blood of Participants With Excess Body Weight

The Influence of Dietary Variety and Course Sequence on Fruit Intake in Preschool-Aged Children

A Study Evaluating the Pharmacokinetics and Relative Bioavailability of Emraclidine Immediate-Release Tablets in Healthy Adult Participants

A Phase 1 AAV Gene Therapy Trial Evaluating Safety and Preliminary Efficacy of RP-A701 in Subjects With BAG3 Dilated Cardiomyopathy

Study to Assess the Pharmacokinetic Bioequivalence of Budesonide and Albuterol With an Alternate Propellant Compared to Current Propellant.